{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:17:45Z","timestamp":1791285465301,"version":"4.1.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T00:00:00Z","timestamp":1502236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0180939","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T13:26:24Z","timestamp":1502285184000},"page":"e0180939","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":157,"title":["Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9685-9183","authenticated-orcid":true,"given":"John J.","family":"Bissler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Chris","family":"Kingswood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Radzikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard A.","family":"Zonnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Belousova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Brakemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrus J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Voi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Peyrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,8,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","article-title":"Epidemiology of tuberous sclerosis","volume":"615","author":"JP Osborne","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"P Curatolo","year":"2008","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"PB Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/j.ajkd.2011.10.013","article-title":"Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition","volume":"59","author":"K Budde","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/jmg.33.6.480","article-title":"A cross sectional study of renal involvement in tuberous sclerosis","volume":"33","author":"JA Cook","year":"1996","journal-title":"J Med Genet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-5347(01)63072-6","article-title":"Renal lesion growth in children with tuberous sclerosis complex","volume":"160","author":"DH Ewalt","year":"1998","journal-title":"J Urol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1464-410X.2004.05046.x","article-title":"An epidemiological study of renal pathology in tuberous sclerosis complex","volume":"94","author":"FJ O'Callaghan","year":"2004","journal-title":"BJU Int"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.ki.5001853","article-title":"Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors","volume":"70","author":"SK Rakowski","year":"2006","journal-title":"Kidney Int"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0022-5347(05)64440-0","article-title":"Contemporary diagnosis and management of renal angiomyolipoma","volume":"168","author":"CP Nelson","year":"2002","journal-title":"J Urol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2214\/AJR.14.14255","article-title":"Differentiation of sporadic versus tuberous sclerosis complex-associated angiomyolipoma","volume":"205","author":"RA Rabenou","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1148\/radiol.2251011477","article-title":"Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture","volume":"225","author":"K Yamakado","year":"2002","journal-title":"Radiology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2015.05.016","article-title":"Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands","volume":"66","author":"MJ Eijkemans","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1464-410X.2009.08649.x","article-title":"Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated","volume":"105","author":"P Sooriakumaran","year":"2010","journal-title":"BJU Int"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/157015912804499537","article-title":"mTOR inhibitors in tuberous sclerosis complex","volume":"10","author":"P Curatolo","year":"2012","journal-title":"Curr Neuropharmacol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"DA Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"JJ Bissler","year":"2013","journal-title":"Lancet"},{"key":"ref17","unstructured":"Afinitor [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2016."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial","volume":"31","author":"JJ Bissler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"ref19","article-title":"Cancer therapy evaluation program: common terminology criteria for adverse events, version 3.0 (CTCAE)","year":"2006"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"AS Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A Confidence Interval for the Median Survival Time","volume":"38","author":"R Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"FX McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"DN Franz","year":"2013","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"DA Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma","volume":"80","author":"DA Krueger","year":"2013","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ana.24523","article-title":"Everolimus for subependymal giant cell astrocytoma: 5-year final analysis","volume":"78","author":"DN Franz","year":"2015","journal-title":"Ann Neurol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","article-title":"Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening","volume":"26","author":"J Trelinska","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"F560","DOI":"10.1152\/ajprenal.00569.2013","article-title":"Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy","volume":"307","author":"BJ Siroky","year":"2014","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0180939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T12:32:23Z","timestamp":1540211543000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0180939"}},"subtitle":[],"editor":[{"given":"Kathrin","family":"Eller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,9]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0180939","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.728367152.793546425","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.728367152.793535788","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,9]]}}}